Strategies for Increasing Pancreatic Tumor Immunogenicity.
Strategies for Increasing Pancreatic Tumor Immunogenicity.
复制标题
DOI：
10.1158/1078-0432.ccr-16-2318
复制
发表时间：
2017-04-01
期刊：
影响因子：
--
通讯作者：
Jaffee EM
中科院分区：
文献类型：
--
作者：
Johnson BA 3rd;Yarchoan M;Lee V;Laheru DA;Jaffee EM
免疫疗法已经改变了多种致命癌症的治疗标准，包括肺癌、头颈癌、胃癌和一些结直肠癌。然而，单药免疫治疗对胰腺腺癌（PDAC）的疗效甚微。越来越多的证据表明，PDAC微环境由免疫细胞、PDAC细胞和基质之间复杂的信号网络组成，导致免疫抑制环境对单药免疫疗法产生抗性。在这篇综述中，我们讨论了免疫治疗敏感性癌症和PDAC之间的差异，PDAC基质和抑制性肿瘤浸润细胞之间的复杂相互作用，促进PDAC的发展和进展，这些复杂网络中的免疫靶点是可药物的，以及支持调节多种PDAC信号的联合药物方法的数据，这将导致改善临床结果。
Immunotherapy has changed the standard of care for multiple deadly cancers including lung, head and neck, gastric, and some colorectal cancers. However, single agent immunotherapy has had little effect in pancreatic adenocarcinoma (PDAC). Increasing evidence suggests that the PDAC microenvironment is comprised of an intricate network of signals between immune cells, PDAC cells, and stroma, resulting in an immunosuppressive environment resistant to single agent immunotherapies. In this review, we discuss differences between immunotherapy sensitive cancers and PDAC, the complex interactions between PDAC stroma and suppressive tumor infiltrating cells that facilitate PDAC development and progression, the immunologic targets within these complex networks that are drugable, and data supporting combination drug approaches that modulate multiple PDAC signals, which should lead to improved clinical outcomes.